PDS Biotech reports FY2025 net loss of $34.5M, updates PDS0101 Phase 3 with interim PFS endpoint

PDS Biotechnology Corp

Net loss of $34.5M ($0.74/share) vs $37.6M ($1.03/share) in 2024; cash $26.7M at year-end.
Amended VERSATILE-003 Phase 3 protocol to add PFS as interim endpoint; aims for accelerated approval and reduced trial cost.
PDS01ADC in mCRPC showed median PFS 9.6 months, PSA decline 40% in early NCI-led Phase 2 data.
New US and Japan patents for PDS0101 extend market protection into 2040s.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PDS Biotechnology Corp reported the year ended December 31, 2025 results: net income approximately $34.5 million, EPS $0.74 per basic and diluted share.

Period: the year ended December 31, 2025
Net income: approximately $34.5 million
EPS: $0.74 per basic and diluted share
Result: reported results

Exact text from the filing

Full Year 2025 Financial Results Net loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and diluted share for the year ended December 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-26-011862

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.